HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Achatzy, R. Articles by Morgan, J. A. Search for Related Content PubMed PubMed Citation Articles by Achatzy, R. Articles by Morgan, J. A.

European Journal of Cardio-Thoracic Surgery, Vol 3, 445-447, Copyright © 1989 by European Association for Cardio-thoracic Surgery

ARTICLES

The diagnosis, therapy and prognosis of diffuse malignant mesothelioma

R Achatzy, W Beba, R Ritschler, H Worn, B Wahlers, HN Macha and JA Morgan
Department of Pneumonology, Lungenklinik Hemer, Federal Republic of Germany.

Between 1969 and 1985, 245 patients with diffuse malignant mesothelioma were treated (157 male, 88 female). The average age was 55.8 years and the sex ratio was 1.8:1 in favour of males. The right side was more frequently affected than the left (56.7% vs. 43.3%). A pleural effusion and dyspnoea were the presenting signs and symptoms in 83.7% of the patients and unilateral chest pain in 64.2%. Noninvasive diagnostic procedures included a chest X-ray and computed tomography of the thorax. Pleural effusion and pleural thickening were detected most frequently. Malignant cells were identified by pleural fluid cytology in 45.3% and by needle biopsy of the pleura in 42.7% of the patients. Forty-five patients were treated conservatively and 200 patients underwent operation: diagnostic thoracotomy (78); partial pleurectomy (72); total pleurectomy (46); extended pleuropneumonectomy (2); partial removal of the diaphragm (1) and total pleurectomy and upper lobectomy (1). The perioperative mortality was 6%. The conservative and postoperative treatment depended on the patients' symptoms and included radiotherapy and chemotherapy alone or in combination. The mean survival time of the 222 non-survivors was 9.2 months. After 1 year, 36% of the patients were still alive, after 2 years, 10.8% and the 5- year survival was 4.1%. The median survival time in patients treated non-operatively was 6 months--a little over half that of the patients treated surgically (10.1 months).

This article has been cited by other articles:

				S. Neragi-Miandoab Multimodality approach in management of malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., January 1, 2006; 29(1): 14 - 19. [Abstract] [Full Text] [PDF]

				R. F. Adams, W. Gray, R. J. O. Davies, and F. V. Gleeson Percutaneous Image-Guided Cutting Needle Biopsy of the Pleura in the Diagnosis of Malignant Mesothelioma Chest, December 1, 2001; 120(6): 1798 - 1802. [Abstract] [Full Text] [PDF]

				R. F. Adams and F. V. Gleeson Percutaneous Image-guided Cutting-Needle Biopsy of the Pleura in the Presence of a Suspected Malignant Effusion Radiology, May 1, 2001; 219(2): 510 - 514. [Abstract] [Full Text]

				J. R. Roberts Surgical Treatment of Mesothelioma: Pleurectomy* Chest, December 1, 1999; 116(suppl_3): 446S - 449S. [Abstract] [Full Text] [PDF]

				V. W. Rusch and E. Venkatraman THE IMPORTANCE OF SURGICAL STAGING IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA J. Thorac. Cardiovasc. Surg., April 1, 1996; 111(4): 815 - 826. [Abstract] [Full Text]